Scholarlink

<p>Elevated homocysteine (Hcy) levels contribute to the onset and progression of childhood epilepsy. However, Hcy-lowering therapies provide limited benefits, suggesting additional pathogenic mechanisms. Here, we identified N-homocysteinylated Cofilin-1 (N-Hcy-CFL1) as a molecular link between elevated Hcy levels and childhood epilepsy. We detected N-Hcy-CFL1 in patients with epilepsy and in a mouse model of hyperhomocysteinemia. Mass spectrometry identified Hcy-dependent lysine modifications in CFL1, and functional assays, including actin depolymerization, the F/G-actin ratio, and axonal elongation, demonstrated impaired CFL1 activity and consequent cytoskeletal rigidity. These changes manifested as increased F-actin levels, increased F/G-actin ratio, and abnormal axonal growth. <i>In vivo</i>, hyperhomocysteinemic mice exhibited prolonged seizures and axonal remodeling, both of which were attenuated by CFL1-directed interventions. Clinically, blood Hcy levels correlated with N-Hcy-CFL1 levels in patients’ brain tissues, supporting its potential as a biomarker. Together, these findings identify N-Hcy-CFL1 as a pathogenic mediator and suggest that N-homocysteinylation is a therapeutic target beyond conventional Hcy-lowering strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

N-Homocysteinylation of Cofilin-1 Aggravates Epileptic Pathophysiology via Disruption of Actin Dynamics

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Xinyu Mei,
  • Yi Liu,
  • Chuantao Fang,
  • Jingjing Guo,
  • Yanfeng Tan,
  • Ying Shi,
  • Jianbo Xiao,
  • Dashi Qi

摘要

Elevated homocysteine (Hcy) levels contribute to the onset and progression of childhood epilepsy. However, Hcy-lowering therapies provide limited benefits, suggesting additional pathogenic mechanisms. Here, we identified N-homocysteinylated Cofilin-1 (N-Hcy-CFL1) as a molecular link between elevated Hcy levels and childhood epilepsy. We detected N-Hcy-CFL1 in patients with epilepsy and in a mouse model of hyperhomocysteinemia. Mass spectrometry identified Hcy-dependent lysine modifications in CFL1, and functional assays, including actin depolymerization, the F/G-actin ratio, and axonal elongation, demonstrated impaired CFL1 activity and consequent cytoskeletal rigidity. These changes manifested as increased F-actin levels, increased F/G-actin ratio, and abnormal axonal growth. In vivo, hyperhomocysteinemic mice exhibited prolonged seizures and axonal remodeling, both of which were attenuated by CFL1-directed interventions. Clinically, blood Hcy levels correlated with N-Hcy-CFL1 levels in patients’ brain tissues, supporting its potential as a biomarker. Together, these findings identify N-Hcy-CFL1 as a pathogenic mediator and suggest that N-homocysteinylation is a therapeutic target beyond conventional Hcy-lowering strategies.